Higher doses of dulaglutide induce weight loss in patients with type 2 diabetes (T2D) regardless of baseline BMI: post hoc analysis of AWARD-11

Background The AWARD-11 trial demonstrated that dulaglutide 3 mg and 4.5 mg once weekly improved glycated hemoglobin (A1C) and bodyweight, compared to dulaglutide 1.5 mg once weekly, in patients with T2D inadequately controlled with metformin monotherapy. The aim of this post hoc analysis was to assess the effect of dulaglutide on bodyweight in clinically relevant baseline body mass index (BMI) categories as defined by clinical practice guidelines.